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2008) were used to determine the medicine treatment cost of 141 RA patients before 
and after treatment with biological drugs (namely inﬂ iximab, adalimumab and etan-
ercept). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 7.06926 (2007) and 
8.27505 (2008)]. RESULTS: Biological drugs represented 81.43% of the total medi-
cine treatment cost of RA patients (n = R25,432,294.04). Other medication (excluding 
biological drugs) prescribed to RA patients before starting with biological items rep-
resented 8.86% (n = R2 254 330.44) of their total medicine treatment cost; those 
prescribed after treatment with biological drugs, represented 3.91% (n = R992,533.62). 
The number of prescriptions for other medication (excl. biological drugs), decreased 
from the period before to the period after treatment with biological drugs from 6271 
to 2120. The average number of the other medicine items (excl. biological) per pre-
scription decreased from 2.79 ± 2.30 before to 2.35 ± 1.86 after treatment with 
biological drugs. The average cost per biological drug (R8 073.61 ± 2 210.46) was 
practically signiﬁ cantly (d > 0.8) higher than the average cost of other medication 
prescribed before (R128.45 ± 155.93) and after (R198.66 ± 888.31) treatment with 
biological drugs. CONCLUSIONS: Although biological drugs used in the treatment 
of RA are very expensive, it seems that the number of other medication prescribed to 
RA patients, as well as the average number of items per prescription decreased after 
treatment therewith. Further research is needed to investigate future medicine treat-
ment cost of RA patients treated with biological drugs.
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OBJECTIVES: To review and analyze evidence on the changes in dose of adalimumab, 
etanercept and inﬂ iximab over time in adult patients with rheumatoid arthritis (RA) 
and the associated impact on treatment costs. METHODS: MEDLINE, EMBASE and 
NHS-EED were systematically searched to identify English language randomised con-
trolled trials, cohort studies and observational studies published between January 
1993 and December 2009. Conference abstracts were also hand searched from 
EULAR (2002 onwards) and ACR (2006 onwards). Studies were selected using pre-
deﬁ ned criteria, using two independent reviewers. Data pertaining to dose change were 
then analyzed through pair-wise, random effects meta-analyses carried out in a fre-
quentist framework with heterogeneity assessed using the I2 statistic. Associated cost 
data were extracted and the impact of change in dose on cost was investigated. 
RESULTS: Forty-ﬁ ve articles met the selection criteria with 23 containing dose change 
data and 26 containing cost data. a signiﬁ cantly greater proportion of patients on 
inﬂ iximab had a dose escalation compared to those on etanercept (odds ratio 0.17 
95% CI 0.07, 0.43; P < 0.001) or adalimumab (odds ratio 0.25 95% CI 0.2, 0.3; P 
< 0.001). On average, 43.3% of inﬂ iximab patients, 7.3% of etanercept patients and 
10.9% of adalimumab patients had their dose increased. RA related costs were on 
average 36% higher in patients who had their inﬂ iximab dose increased compared to 
4% in patients on etanercept. No suitable data for adalimumab were available. 
CONCLUSIONS: A signiﬁ cantly greater proportion of inﬂ iximab patients required 
dose escalation compared to etanercept and adalimumab patients. There is some 
evidence to suggest that the escalation in dose required to maintain clinical beneﬁ t, 
results in substantially higher costs of treating RA.
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OBJECTIVES: In Italy the recent update of the DRG system has led to evaluate the 
effect on the diffusion of new therapies. The Interspinous Process Device (IPD) implan-
tation represents an innovative strategy for different degenerative spinal pathologies 
with potential clinical and economic advantages. The aim of this study is to evaluate 
the hospitalization costs for IPD procedure according to a micro-costing approach and 
to compare it with current regional DRG tariffs. METHODS: The project, conducted 
from the hospital perspective, is performed in one pilot centre (Varese hospital), 
regional benchmark for this kind of procedure in which learning curve is considered 
completed. The cost analysis is based on the clinical pathway drawn up from the 
information provided by the medical team. Resource use including staff time, diag-
nostic tests, drugs, consumables and technology equipment utilization are collected 
from interviews to the team. Operating room costs, administrative and general costs 
and follow up hospital resource consumption are derived from hospital accounting 
data. Unit costs are collected either from hospital accounting or regional tariffs for 
specialist services. RESULTS: The total average cost estimated for a patient submitted 
to an IPD implantation is c5644, with an average LOS of 2.7 days. The average cost 
for the implantation of 1 IPD is c4515, value assigned to increase to c7087 for mul-
tilevel approaches with the implantation of 2 devices in the same procedure (42% of 
cases). Excluding general costs and the number of IPDs implanted, the main key cost 
driver are consumables and devices (62%), and operating room costs (16%). CON-
CLUSIONS: The regional tariff of the DRG related to this procedure (Lombardia 
Region, DRG 500, version 24) does not cover the hospitalization costs estimated, 
especially for the multilevel approaches. This leads to consider the effects of current 
reimbursement on the adoption of innovative therapy.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, inﬂ ammatory 
disease that affects physical functioning and quality-of-life and is associated with 
premature mortality and substantial economic burden. We aimed to assess cost-
effectiveness of tocilizumab added to disease-modifying antirheumatic drugs 
(DMARD) in patients with active RA despite DMARD therapy from the Mexican 
public health care system perspective. METHODS: Two models were designed to 
compare tocilizumab 8 mg/kg every 4 weeks; inﬂ iximab 3 mg/kg (weeks 0, 2, 6, 14 
and 22); etanercept 25 mg twice a week and adalimumab 40 mg every other week. 
First model included only 6-month acquisition costs of drugs and infusion-related cost 
for inﬂ iximab and tocilizumab; the second was a Markov model with four states 
deﬁ ned according to Disease Activity Score (DAS-28). Indirect comparison techniques 
were needed to adjust American College of Rheumatology (ACR) responses rates 
found in 10 clinical trials with biological agents. ACR70 at week 24 and overall days 
spent in remission during 5 years were main outcomes. Unit costs of medications were 
gathered from public bids; an expert panel was constituted to estimate 3-month 
resource use by health state. All costs are expressed in 2009 US dollars. RESULTS: 
First six-month costs were lower with tocilizumab (USD$4418) than with etanercept 
(USD$5,020), inﬂ iximab (USD$5484) and adalimumab (USD$5655). Adjusted 
ACR70 response rate was higher for tocilizumab than for anti-tumor necrosis factor 
(TNF) agents: 26% vs. 19%, 18% and 12% for adalimumab, etanercept and inﬂ ix-
imab, respectively. Markov model estimates show savings of USD$623 up to 
USD$1321 per patient treated with tocilizumab instead of anti-TNF. Tocilizumab was 
also associated with mean gains of 9, 12 and 20 days in remission compared to 
etanercept, adalimumab and inﬂ iximab. CONCLUSIONS: When used instead of anti-
TNF agents, add-on treatment with tocilizumab brings both health beneﬁ ts and cost-
savings for RA patients with inadequate response to previous DMARD therapy.
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BACKGROUND: Golimumab is a novel TNF-α inhibitor licensed to treat patients with 
active PsA. Although its clinical efﬁ cacy has been proven in clinical trials, its cost-
effectiveness is yet to be established. OBJECTIVES: To estimate the cost-effectiveness 
of golimumab among patients with active PsA from the UK NHS perspective. 
METHODS: A decision analytic model was used to simulate progression of a hypotheti-
cal cohort of active PsA patients on golimumab and other TNF-α inhibitors as well as 
palliative care. The clinical evidence was derived from clinical trials of TNF-α inhibitors 
and compared using mixed treatment models. The primary outcome measure was 
quality adjusted life-years (QALYs) estimated based on change in Health Assessment 
Questionnaire (HAQ) and Psoriasis Area Severity Index (PASI) from baseline. The 
annual acquisition cost of golimumab was assumed to be identical to annual cost of 
other subcutaneous TNF-α inhibitors. The resource use costs and outcomes were dis-
counted at 3.5% over a period of 40 years. The uncertainty surrounding important 
variables was further explored using probabilistic sensitivity analyses (PSA). RESULTS: 
TNF-α inhibitors were signiﬁ cantly superior to palliative care but comparable to each 
other on Psoriatic Arthritis Response Criteria (PsARC), HAQ and PASI response. The 
incremental cost-effectiveness ratio (ICERs) for golimumab compared to palliative care 
was £16,811 for PsA patients and £16,245 for a subgroup of PsA patients with signiﬁ -
cant psoriasis. At an acceptability threshold of £30,000 per QALY, the probability of 
golimumab being cost-effective is 89%. CONCLUSIONS: Once monthly, golimumab 
is a cost-effective treatment alternative for patients with active PsA. With its patient 
focussed attributes, golimumab is likely to offer additional choice in PsA treatment.
PMS35
COST-EFFECTIVENESS OF TERIPARATIDE IN PATIENTS WITH 
GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN SWEDEN
Smolen LJ1, Gregor Z2, Barrett A3, Myrén KJ4, Toll A5
1Medical Decision Modeling Inc., Indianapolis, IN, USA; 2Eli Lilly & Company, Prague, Czech 
Republic; 3Eli Lilly & Company Ltd, Windlesham, Surrey, UK; 4Eli Lilly & Company, 
Windlesham, UK; 5Eli Lilly Sweden AB, Solna, Sweden
OBJECTIVES: Glucocorticoid induced osteoporosis is the most common cause of 
secondary osteoporosis. The objective of this study was to estimate the cost-effective-
ness of teriparatide in patients with Glucocorticoid induced osteoporosis in Sweden. 
METHODS: A cost-effectiveness analysis was developed to evaluate the direct medical 
and tertiary care costs and clinical outcomes of an 18-month regimen of daily teripa-
ratide in patients with glucocorticoid induced osteoporosis (GIO). a Monte Carlo 
simulation was used to model the cost and effects of a simulated cohort of 100,000 
patients with GIO treated with teriparatide compared to no teriparatide treatment. 
The model simulated the course of events in 6-month cycles in individual patients over 
a lifetime horizon. During each cycle the patients were at risk of experiencing clinical 
